This site describes the schedules of the Canadian Controlled Drugs and Substances Act (CDSA).
The CDSA is the federal legislation that spells out which chemicals and plants Canadian citizens may not grow, buy, sell, swallow, hold, or otherwise lust after.
If you do grow, buy, sell, swallow, hold, or otherwise lust after any of these chemicals or plants you may be arrested, fined, jailed, or all three.
Also described here are the United Kingdom Misuse of Drugs Act (MDA), the United Nations Drugs and Substances under International Control, the United States Controlled Substances Act (CSA), and substances controlled by the European Union.
Controlled Drugs and Substances Act
Controlled Substances Act
- 17 Jul 2015 Final rule 80 FR 42381: Temporary Placement of Acetyl Fentanyl into Schedule I.
- 03 Jun 2015 Proposed rule 80 FR 31521: Removal of [123I]Ioflupane from Schedule II.
- 15 May 2015 Final rule 80 FR 27854: Extension of Temporary Placement of UR-144, XLR11, and AKB48 in Schedule I.
- 14 May 2015 Proposed rule 80 FR 27611: Placement of UR-144, XLR11, and AKB48 Into Schedule I.
- 20 Mar 2015 Final rule 80 FR 14842: Substances Temporarily Controlled Under Schedule I. A bit of Schedule I Section (h) housekeeping. Technical amendments, not substantive changes.
- 30 Jan 2015 Final rule 80 FR 5042: Temporary Placement of Three Synthetic Cannabinoids [UR-144, XLR11, AKB48] Into Schedule I.
- 23 Jan 2015 Final rule 80 FR 3468: Removal of Naloxegol From Control.
- 18 Dec 2014 Act of Congress H.R. 4771, 113 Cong., 2nd Sess.: Designer Anabolic Steroid Control Act of 2014. Bill H.R. 4771 redefines “anabolic steroid,” greatly expanding the reach of the CSA. This new definition is similar in spirit to the Analogue Act, which expanded the scope of Schedules I and II to include “substantially similar” substances.
- 29 Sep 2014 Final rule 79 FR 51243: Placement of Suvorexant into Schedule IV.
- 06 Oct 2014 Final rule 79 FR 49661: Rescheduling of Hydrocodone Combination Products From Schedule III to Schedule II.
- 29 Sep 2014 Final rule 79 FR 51243: Placement of Suvorexant into Schedule IV.
- 14 Aug 2014 Final rule 79 FR 37623: Placement of Tramadol Into Schedule IV.
- 31 Mar 2014 Final rule 79 FR 10985: Placement of Alfaxalone into Schedule IV.
- 07 Mar 2014 Final rule 79 FR 12938: Temporary Placement of 10 Synthetic Cathinones [4-MEC, 4-MePPP, α-PVP, Butylone, Pentedrone, Pentylone, 4-FMC, 3-FMC, Naphyrone, α-PBP] Into Schedule I.
- 10 Feb 2014 Final rule 79 FR 7577: Temporary Placement of Four Synthetic Cannabinoids [PB-22, 5F-PB-22, AB-FUBINACA, ADB-PINACA] Into Schedule I.
- 02 Dec 2013 Final rule 78 FR 72013: Placement of Perampanel into Schedule III.
- 15 Nov 2013 Final rule 78 FR 68716: Temporary Placement of Three Synthetic Phenethylamines [25I-NBOMe, 25B-NBOMe, 25C-NBOMe] Into Schedule I.
- 16 May 2013 Final rule 78 FR 28735: Temporary Placement of Three Synthetic Cannabinoids [UR-144, 5F-UR-144 (XLR11), APINACA (AKB48)] Into Schedule I.
- 07 Jun 2013 Final rule 78 FR 26701: Placement of Lorcaserin Into Schedule IV.
- 12 Apr 2013 Final rule 78 FR 21818: Placement of Methylone Into Schedule I.
Misuse of Drugs Act
- On 27 June 2015 Misuse of Drugs Act 1971 (Temporary Class Drug)(No. 2) Order 2015 [re]designated five existing and two additional substances—and their salts—as temporary class drugs:
- On 28 May 2015 the Psychoactive Substances Bill 2015 was tabled: “New legislation [to] ban the new generation of psychoactive drugs.” The British flair for understatement is striking.
- On 10 Apr 2015 Misuse of Drugs Act 1971 (Temporary Class Drug) Order 2015 designated five substances as temporary class drugs:
- 3,4-Dichloromethylphenidate (3,4-DCMP)
- Isopropylphenidate (IPP; IPPD)
- Methylnaphthidate (HDMP-28)
Each is a potentially-fatal analogue of methylphenidate, the harmless wonder-drug used for over a half-century to help millions of young boys with damaged brains STFU and pay attention.
Rescued from their otherwise inevitable spiral into degeneracy, crime and madness, many became captains of industry who would doubtless credit methylphenidate for their success—particularly those in the pharmaceutical racket.
- On 11 Mar 2015 The Misuse of Drugs Act 1971 (Amendment) Order 2015 made MT-45 and 4,4′-DMAR Class A drugs.
- On 7 Jan 2015 The Misuse of Drugs Act 1971 (Amendment) (No. 2) Order 2014, the third and final version (see below) came into force.
- On 17 Dec 2014 The Misuse of Drugs Act 1971 (Amendment) Order 2015 [draft version] proposed to make MT-45 and 4,4′-DMAR Class A drugs.
- On 30 Oct 2014 The Misuse of Drugs Act 1971 (Amendment) (No. 2) Order 2014 [draft version 2] replaced the earlier draft, correcting some of the errors.
- On 16 July 2014 The Misuse of Drugs Act 1971 (Amendment) (No. 2) Order 2014 [draft version 1] proposed to criminalize anyone who may have, take or sell:
They’ve made a bit of a hash of this one. [With thanks to Sean D. for alerting me.]
- An infinite number of tryptamines (of which an infinite number are not known to exist).
- Five ‘LSD related’ compounds (If it looks like a duck…).
- On 24 June 2014 The Misuse of Drugs Act 1971 (Amendment) Order 2014 makes Khat (i.e. the leaves, stems or shoots of the plant of the species Catha edulis) a Class C substance.
- On 10 June 2014 The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014, a near-impenetrable omnibus amendment:
- Added the N-benzyl analogues of any compound derived from pretty much everything in PiHKAL (but not N-Benzyl-MDA), including any and all benzyl substituents, to Class A. An infinity of substances.
- Added Benzofuran, Indole and Indane, along with their didehydro counterparts, with a 2-aminoethyl substituent (which they incorrectly cite as 2-ethylamino—a nonsensical name I think) at any phenyl position, including almost limitless additional substitution of the ring system and/or the 2-aminoethyl substituent, to Class B. Six more infinities.
- Moved Ketamine to Class B from Class C.
- Added Lisdexamphetamine to Class B.
- Added Tramadol, Zaleplon and Zopiclone to Class C.
- On 10 June 2013 S.I. 2013/1294 designated 14±4 substances as temporary class drugs.
- On 26 Feb 2013, S.I. 2013/239 added infinitely more synthetic cannabinoids to the previously scheduled infinity. Similarly, an infinite number of aryl cyclohexanamines (e.g. Ketamine, Methoxetamine and friends) are now scheduled, as is, uniquely, O-Desmethyltramadol.
- On 13 June 2012 S.I. 2012/1390 scheduled a countable infinity of Pipradrol analogues, and Phenazepam.
Drugs and Substances under International Control
Substances Controlled by the European Union
- Includes proposal of 25 June 2013 for a Council Decision on submitting 5-(2-aminopropyl)indole (5-IT) to control measures.
Readings on drug law design and policy—the good, the bad, and the unworkable.
- Hudson AL, Lalies MD, Baker GB, Wells K, Aitchison KJ. (2014). Ecstasy, Legal Highs and Designer Drug Use: A Canadian Perspective. Drug Science, Policy and Law, 1.
- DeBeck K, Wood E, Montaner J, Kerr T. (2009).
Canada’s New Federal “National Anti-Drug Strategy”: An Informal Audit of Reported Funding Allocation International Journal of Drug Policy 28: 188–191.
- Wood E, Kerr T, Tyndall MW, Montaner JSG. (2008).
The Canadian government’s treatment of scientific process and evidence: Inside the evaluation of North America’s first supervised injecting facility International Journal of Drug Policy 19: 220–225.
- Wodak A (2008)
Going Soft on Evidence and Due Process: Canada Adopts US Style Harm Maximization International Journal of Drug Policy 19: 226–228.
- Phillips GF (1967)
Some chemical aspects of drug legislation. http://doi.org/10.1016/S0015-7368(67)70367-9
- King LA (2009)
Forensic chemistry of substance misuse: a guide to drug control. Cambridge, UK: Royal Society of Chemistry. 249 p.
- King LA (2013)
Chapter 1 - Legal Classification of Novel Psychoactive Substances: An International Comparison. In: Dargan PI, Wood DM, editors. Novel Psychoactive Substances. Boston: Academic Press. pp. 3–27.
- King LA (2013)
Legal controls on cannabimimetics: An international dilemma? Drug Testing and Analysis: 6: 80-87.
- King LA, Ujváry I, Brandt SD (2013)
Drug laws and the “derivative” problem Drug Testing and Analysis.
- Nutt DJ, King LA, Nichols DE (2013)
Effects of Schedule I drug laws on neuroscience research and treatment innovation. Nature Reviews Neuroscience 14: 577–585.
- ForensicToxGuy (2013)
Analogue or not an analogue: that is the question! The Dose Makes The Poison—the incessant ramblings of a forensic toxicologist and drug chemist. dosemakespoison.blogspot.ca
I would like to share with you the mountains of solid, empirical evidence Health Canada has amassed on new psychoactive substances. And, if any existed, I surely would share it. Sadly, as far as I can tell Health Canada stopped doing anything approaching credible science long ago. PowerPoint bullet lists of tabloid headlines is about their current level of intellectual engagement.
Fortunately not every country has abdicated public health in favour of empty self-congratulatory piffle. Italy, for example, just published 1700 pages of hard, analytical data on over 250 new drugs. There is more substantive content in this single document than the whole of Health Canada’s truly pathetic and embarrassingly irrelevant website. Hyperbole? No. Take a look at their Science and Research Page and tell me that fills you with patriotic pride.
I have tried to ensure that the text and structures listed here are complete and correct. I apologize for any errors or omissions. Please report any mistakes you detect or suspect, as well as any suggestions for improving this site, to Steve Chapman.
Updated 27 July 2015 ·
This website is provided for general information purposes only. It is not intended to replace official versions of legislation. It is not meant as legal or other professional advice. If you require specific legal advice on any issue, please consult a lawyer.
Although every reasonable effort is made to assure accuracy, laws and regulations governing controlled drugs and substances change over time, and often without advance notice. The information here is presented without warranty, either expressed or implied, as to its accuracy, timeliness, or completeness.